203 related articles for article (PubMed ID: 25498784)
1. Evolution of drug reimbursement in Canada: the Pan-Canadian Pharmaceutical Alliance for new drugs.
Husereau D; Dempster W; Blanchard A; Chambers J
Value Health; 2014 Dec; 17(8):888-94. PubMed ID: 25498784
[TBL] [Abstract][Full Text] [Related]
2. Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.
Rocchi A; Mills F
J Popul Ther Clin Pharmacol; 2018 Aug; 25(2):e12-e22. PubMed ID: 30725539
[TBL] [Abstract][Full Text] [Related]
3. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
[TBL] [Abstract][Full Text] [Related]
4. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
Rocchi A; Menon D; Verma S; Miller E
Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
[TBL] [Abstract][Full Text] [Related]
5. Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.
Rawson NSB; Stewart DJ
Clinicoecon Outcomes Res; 2024; 16():437-445. PubMed ID: 38812711
[TBL] [Abstract][Full Text] [Related]
6. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.
Binder L; Ghadban M; Sit C; Barnard K
Curr Oncol; 2022 Mar; 29(3):1514-1526. PubMed ID: 35323327
[TBL] [Abstract][Full Text] [Related]
8. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
[TBL] [Abstract][Full Text] [Related]
9. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers.
Morgan SG; Thomson PA; Daw JR; Friesen MK
Health Policy; 2013 Oct; 112(3):248-54. PubMed ID: 23809914
[TBL] [Abstract][Full Text] [Related]
10. Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
Rawson NSB
Orphanet J Rare Dis; 2022 Jun; 17(1):218. PubMed ID: 35698235
[TBL] [Abstract][Full Text] [Related]
11. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved?
Drummond M
J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475
[TBL] [Abstract][Full Text] [Related]
12. Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail: An Empirical Analysis of 5 Years' Experience.
Ludwig S; Dintsios CM
Value Health; 2016 Dec; 19(8):1016-1025. PubMed ID: 27987628
[TBL] [Abstract][Full Text] [Related]
13. Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces.
Morgan SG; Thomson PA; Daw JR; Friesen MK
BMC Health Serv Res; 2013 Jan; 13():34. PubMed ID: 23363626
[TBL] [Abstract][Full Text] [Related]
14. International best practices for negotiating 'reimbursement contracts' with price rebates from pharmaceutical companies.
Morgan S; Daw J; Thomson P
Health Aff (Millwood); 2013 Apr; 32(4):771-7. PubMed ID: 23569058
[TBL] [Abstract][Full Text] [Related]
15. Progress on drug pricing negotiations in China.
Tang M; Song P; He J
Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
[TBL] [Abstract][Full Text] [Related]
16. External referencing and pharmaceutical price negotiation.
Garcia Mariñoso B; Jelovac I; Olivella P
Health Econ; 2011 Jun; 20(6):737-56. PubMed ID: 20577969
[TBL] [Abstract][Full Text] [Related]
17. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
[TBL] [Abstract][Full Text] [Related]
18. Closing the Gaps to Timely Patient Access: Perspectives on Conditional Funding Models.
Glennie J; Villalba E; Wheatley-Price P
Curr Oncol; 2022 Feb; 29(2):981-988. PubMed ID: 35200582
[TBL] [Abstract][Full Text] [Related]
19. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.
Dranitsaris G; Truter I; Lubbe MS; Cottrell W; Spirovski B; Edwards J
J Eval Clin Pract; 2012 Apr; 18(2):343-51. PubMed ID: 21087368
[TBL] [Abstract][Full Text] [Related]
20. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
Yong JH; Beca J; Hoch JS
Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
